2141-V11

2141-V11 is a Fc-engineered monoclonal antibody that acts as an agonist of CD40 (Tumor necrosis factor receptor superfamily member 5), a member of the tumor necrosis factor receptor superfamily expressed on antigen-presenting cells. By binding to CD40, 2141-V11 stimulates immune cell activation and promotes antitumor immune responses. The antibody has been engineered for enhanced binding to the inhibitory FcγRIIB receptor, which increases its immunostimulatory activity and antitumor efficacy compared to earlier anti-CD40 antibodies. Preclinical studies demonstrated that intratumoral administration can induce local and systemic antitumor effects with reduced toxicity compared to systemic delivery. Clinical trials have shown promising safety and preliminary efficacy in patients with metastatic cancers such as melanoma, breast carcinoma, bladder cancer, and malignant glioma. The drug was initially developed by Duke University and is currently in phase 2 clinical development[1][3][4][5][6].

Other names

Fc-engineered anti-CD40 agonist antibody 2141-V11